ICD-10-CM Billable Code

K63.8212

Small intestinal bacterial overgrowth, hydrogen sulfide-subtype

Clinical Classification Guidelines

Medical Intelligence & Overview

Small Intestinal Bacterial Overgrowth (SIBO) occurs when there is an abnormal increase in the number or types of bacteria in the small intestine. The hydrogen sulfide subtype of SIBO is characterized by overgrowths of bacteria that produce hydrogen sulfide gas. This condition can disrupt normal digestion and absorption, leading to a variety of digestive symptoms. Recognizing and understanding this subtype helps in appropriate diagnosis and management.

Causes & Symptoms

Clinical Causes: Impaired motility of the small intestine, leading to slowed transit and bacterial accumulation Structural abnormalities in the gastrointestinal tract, such as strictures or diverticula Use of medications that alter gut flora, such as antibiotics or proton pump inhibitors Underlying conditions like diabetes mellitus or scleroderma that affect normal gut function Poor dietary habits contributing to bacterial overgrowth Previous abdominal surgeries that can alter the gut anatomy and motility

Key Symptoms: Bloating and abdominal distension Excessive gas production, often with a foul odor Diarrhea or sometimes constipation Abdominal pain or discomfort Malnutrition and weight loss in severe cases Steatorrhea or greasy, foul-smelling stools Nutritional deficiencies due to malabsorption

Diagnostic & Treatment

Diagnosis Path: Diagnosis of SIBO, including the hydrogen sulfide subtype, typically involves breath testing. The patient breathes into a collection device after ingestion of a specific sugar substrate, such as lactulose or glucose. Elevated levels of hydrogen sulfide gas on the breath test indicate bacterial overgrowth. Additional diagnostic tools may include small intestine imaging and endoscopy to rule out other causes of symptoms. Laboratory tests to assess nutritional status and rule out other gastrointestinal disorders may also be performed.

Treatment Protocols: Treatment strategies aim to reduce bacterial overgrowth and manage symptoms. Common approaches include: - **Antibiotic therapy:** Specific antibiotics are prescribed to target overgrown bacteria. Rifaximin is frequently used, but other antibiotics may be selected based on individual cases. - **Dietary modifications:** A low FODMAP diet or specific carbohydrate restrictions may help reduce symptoms. - **Prokinetic agents:** Medications that enhance gut motility can reduce bacterial stagnation. - **Addressing underlying conditions:** Managing any related health issues such as diabetes or structural abnormalities. - **Probiotics:** Although evidence is mixed, some patients may benefit from probiotic supplements. - **Supportive care:** Nutritional support and supplementation to address deficiencies. It is important to consult with a healthcare provider for a comprehensive management plan tailored to individual health needs.

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.

Clinical Advice & FAQs

Billing Guidance

Is K63.8212 a billable ICD-10 code?
Yes, K63.8212 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.

Documentation

How do I report K63.8212?
Clinical documentation must specify the nature of Small intestinal bacterial overgrowth, hydrogen sulfide-subtype and any associated comorbidities for accurate reporting.

Cite this Clinical Reference

Clinical Meta Tags

small bacterial hydrogen intestinal